Norlén B J, Fritjofsson A, Grönquist L, Gunnarsson P O, Johansson S A, Plym-Forshell G
Eur Urol. 1987;13(3):193-7. doi: 10.1159/000472772.
To evaluate the appropriate dosage of polyestradiol phosphate (PEP, Estradurin) as single-drug therapy, patients with metastatic prostatic carcinoma were given 80, 160 or 240 mg PEP every 4 weeks for at least 6 months. Injection of PEP was followed by rising plasma concentrations of estradiol in the first 2 weeks and slight fall in the next 2 weeks. Testosterone levels fell rapidly in the first 7 days and rose slightly in the following 3 weeks. Steady-state levels were reached after 2 months at the two lowest doses and after 4 months at the highest dose. Steady-state estradiol values increased in linear proportion to the dose. The steady-state concentrations of testosterone were about 45, 25 and 15% of the pretreatment values in the respective groups. At least 160 mg PEP at 4-week intervals is appropriate when the drug is used alone.
为评估聚磷酸雌二醇（PEP，爱斯妥）单药治疗的合适剂量，转移性前列腺癌患者每4周接受80、160或240mg PEP治疗，至少持续6个月。注射PEP后，血浆雌二醇浓度在最初2周上升，随后2周略有下降。睾酮水平在最初7天迅速下降，随后3周略有上升。最低的两个剂量在2个月后达到稳态水平，最高剂量在4个月后达到稳态水平。稳态雌二醇值与剂量呈线性比例增加。各治疗组睾酮的稳态浓度分别约为治疗前值的45%、25%和15%。当单独使用该药时，每4周间隔给予至少160mg PEP是合适的。
